A Prospective Multi-center Phase III Randomized Controlled Trial

See also
Status	Clinical Trial	Phase
Completed	`NCT03053219` - Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment	Phase 1
Active, not recruiting	`NCT03088540` - Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3
Completed	`NCT03044626` - Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC	Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT03053219 - Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment

Phase 1

Active, not recruiting

NCT03088540 - Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

NCT03044626 - Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT02607592
Study type	Interventional
Source	Sun Yat-sen University
Contact	li-kun chen, Doctor
Phone	13798019964
Email	chenlk@sysucc.org.cn
Status	Recruiting
Phase	Phase 3
Start date	August 2015
Completion date	December 2022

A Prospective Multi-center Phase III Randomized Controlled Trial — NACA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms